Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2013 Oct;34(4):309-12.
doi: 10.4103/0971-5851.125252.

Primary mediastinal seminoma; resistance and relapse: An aggressive entity

Ankita Nachankar  1 , Rahul Krishnatry  1 , Amit Joshi  2 , Vanita Noronha  2 , Jai Prakash Agarwal  1
Affiliations
Case Reports

Primary mediastinal seminoma; resistance and relapse: An aggressive entity

Ankita Nachankar et al. Indian J Med Paediatr Oncol. 2013 Oct.

Abstract

Seminoma is one of the most radio and chemo sensitive tumors. Aggressive variant of primary mediastinal seminoma (PMS) are rarely described in the literature. We here discuss an interesting case of young male (22 years) presenting with superior vena cava syndrome due to PMS that showed poor response to conventional platinum based chemotherapy and radiotherapy. Furthermore, with a short disease free interval (one year) relapsed at unusual sites of bone and soft-tissue deposits in check. This emphasizes the importance of identifying methods to pre-screen such aggressive variants for more effective treatment options.

Keywords: Bone metastasis; chemoresistance; extra-gonadal germ cell tumor; mediastinal seminoma; radio-resistance; soft-tissue metastasis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Computed tomography chest showing primary mediastinal seminoma with involvement of major vessels; especially invasion of superior vena cava
Figure 2
Figure 2
Computed tomography head neck showing soft-tissue deposit in check (*)
See this image and copyright information in PMC

References

    1. Bokemeyer C, Nichols CR, Droz JP, Schmoll HJ, Horwich A, Gerl A, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: Results from an international analysis. J Clin Oncol. 2002;20:1864–73. - PubMed
    1. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28:3388–404. - PubMed
    1. Bachner M, Loriot Y, Gross-Goupil M, Zucali PA, Horwich A, Germa-Lluch JR, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: A retrospective validation of the SEMPET trial. Ann Oncol. 2012;23:59–64. - PubMed
    1. Müller J, Schrader AJ, Jentzmik F, Schrader M. Assessment of residual tumours after systemic treatment of metastatic seminoma: 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography – Meta-analysis of diagnostic value. Urologe A. 2011;50:322–7. - PubMed
    1. Iwasa S, Ando M, Ono M, Hirata T, Yunokawa M, Nakano E, et al. Relapse with malignant transformation after chemotherapy for primary mediastinal seminoma: Case report. Jpn J Clin Oncol. 2009;39:456–9. - PubMed

Publication types